TBio-4101
- Generic Name
- TBio-4101
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
Phase 1
Recruiting
- Conditions
- Squamous Cell Carcinoma of Head and NeckMetastatic Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2025-03-12
- Target Recruit Count
- 15
- Registration Number
- NCT06236425
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
Phase 1
Recruiting
- Conditions
- Unresectable MelanomaNon-Cutaneous MelanomaMetastatic MelanomaOcular MelanomaIris MelanomaAcral MelanomaUveal MelanomaMucosal MelanomaCutaneous MelanomaConjunctival Melanoma
- Interventions
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2025-02-07
- Target Recruit Count
- 25
- Registration Number
- NCT05628883
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Breast CancerColorectal CancerCutaneous MelanomaUveal MelanomaNon-Small Cell Lung CancerHead and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Turnstone Biologics, Corp.
- Target Recruit Count
- 31
- Registration Number
- NCT05576077
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath